tldrdailynews.com logo

Regenxbio hits milestone in Duchenne gene therapy ahead of FDA filing

1 min read
Source: statnews.com
Regenxbio hits milestone in Duchenne gene therapy ahead of FDA filing
Photo: statnews.com
TL;DR

Regenxbio announced its experimental Duchenne muscular dystrophy gene therapy produced sufficient levels of a miniaturized muscle protein in a clinical trial, paving the way for an FDA submission and aiming to improve on Sarepta’s Elevidys in both efficacy and safety, amid ongoing safety concerns surrounding the competitor.

Topics:businesshealthcare#biotechnology#clinical-trials#duchenne-muscular-dystrophy#gene-therapy#healthcare#pharmaceuticals
Share this article
  1. Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission  statnews.com
  2. Regenxbio reaps pivotal win for Duchenne gene therapy  Fierce Biotech
  3. Regenxbio Shares Rise After Positive Duchenne Trial Results  Yahoo Finance
  4. REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202  PR Newswire
  5. Regenxbio's Duchenne study succeeded. Will it be enough to convince the FDA?  Endpoints News

Want the full story? Read the original reporting

Read on statnews.com